Benjamin F. Edwards & Company, Inc. Galectin Therapeutics Inc Transaction History

Benjamin F. Edwards & Company, Inc.

$5.69 Billion
Q2 2024

A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 1,775 shares of GALT stock, worth $7,366. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,775

Previous 1,775 -0.0%

Holding current value

$7,366

Previous $4,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	SELL	$1.6 - $2.18 $6,025 - $8,209	-3,766 Reduced 67.97%	1,775 $3,000
Q2 2023 Aug 15, 2023	SELL	$1.32 - $2.08 $4,745 - $7,477	-3,595 Reduced 39.35%	5,541 $8,000
Q1 2023 Apr 27, 2023	SELL	$1.1 - $2.4 $27,803 - $60,662	-25,276 Reduced 73.45%	9,136 $19,000
Q4 2022 Feb 07, 2023	BUY	$1.03 - $1.66 $15,611 - $25,160	15,157 Added 78.72%	34,412 $39,000
Q2 2022 Aug 12, 2022	SELL	$1.19 - $1.74 $10,211 - $14,930	-8,581 Reduced 30.83%	19,255 $25,000
Q1 2022 May 04, 2022	SELL	$1.61 - $2.31 $2,864 - $4,109	-1,779 Reduced 6.01%	27,836 $45,000
Q4 2021 Feb 07, 2022	BUY	$2.07 - $3.8 $12,451 - $22,857	6,015 Added 25.49%	29,615 $61,000
Q3 2021 Nov 02, 2021	SELL	$2.59 - $4.15 $28,730 - $46,035	-11,093 Reduced 31.97%	23,600 $92,000
Q2 2021 Aug 11, 2021	BUY	$2.07 - $5.1 $49,665 - $122,364	23,993 Added 224.23%	34,693 $111,000
Q1 2021 May 14, 2021	BUY	$1.96 - $2.57 $1,960 - $2,570	1,000 Added 10.31%	10,700 $23,000
Q3 2020 Nov 13, 2020	BUY	$2.53 - $3.64 $20,746 - $29,848	8,200 Added 546.67%	9,700 $26,000
Q4 2018 Jan 31, 2019	BUY	$3.43 - $5.74 $5,145 - $8,610	1,500 New	1,500 $5,000

Others Institutions Holding GALT

# of Institutions

Shares Held

9.53M

Call Options Held

587K

Put Options Held

2.02M

View Full List

About GALECTIN THERAPEUTICS INC

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $247M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

More about GALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Benjamin F. Edwards & Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Benjamin F. Edwards & Company, Inc. with notifications on news.

Account

Benjamin F. Edwards & Company, Inc. Galectin Therapeutics Inc Transaction History